Roche’s Alecensa kept people with lung cancer alive longer than Pfizer’s Xalkori

News Hour:

Roche’s Alecensa kept people with a specific lung cancer alive longer without their disease progressing than Pfizer’s Xalkori, the Swiss drugmaker said on Monday, as it seeks to move in on the U.S. company’s share of early treatment of the disease. Roche now plans to submit the results of the Phase III study to global health regulators, it said in its statement.

Alecensa, approved since 2015 in people with advanced ALK-positive non-small cell lung cancer who have failed on Xalkori, is now being trialed head-to-head against Pfizer’s medication as an initial treatment, reports Reuters.


This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments
Scroll Up
%d bloggers like this: